Nicholas Wilcken, Joint Co-ordinating Editor of Cochrane Breast Cancer, outlined significant advances in breast cancer treatment in The Conversation earlier this month. His wide-ranging article highlights the group's updated High dose chemotherapy review, which concludes high dose chemo does not improve survival rates and carries an increased risk of treatment-related deaths in women with early poor prognosis breast cancer. The implications of these important and definitive findings are explored further in the latest Cochrane Library editorial.